Compositions comprising antibodies to human ido-2

Abstract

Antibodies that specifically or preferentially bind to human IDO2, epitope-binding fragments, and compositions containing one or more of such antibodies or fragments are disclosed, as are uses of these compositions for treating diseases, such as autoimmune disease.

What is claimed is: 
     
         1 . A recombinant, synthetic or monoclonal human antibody or antibody construct that binds to an epitope, or a fragment of said antibody that specifically or preferentially binds human IDO2, said antibody or construct comprising at least one heavy chain variable region CDR selected from SEQ ID NO: 16, 18 or 20. 
     
     
         2 . The recombinant, synthetic or monoclonal human antibody or antibody construct according to  claim 1 , further comprising at least one heavy chain variable domain sequence that is at least 80% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs. 10, 12 or 14. 
     
     
         3 . The recombinant, synthetic or monoclonal human antibody or antibody construct according to  claim 1 , further comprising a light chain variable domain sequence that is at least 80% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 2. 
     
     
         4 . The recombinant, synthetic or monoclonal human antibody or antibody construct according to  claim 1 , wherein said antibody is a chimeric antibody, a humanized antibody, a human antibody, a CDR-grafted antibody, a multi-specific binding construct that can bind two or more targets, a dual specific antibody, a bi-specific antibody or a multi-specific antibody, or an affinity matured antibody. 
     
     
         5 . The recombinant, synthetic or monoclonal human antibody or antibody construct according to  claim 1 , wherein said fragment is a single-domain antibody (sdAb), a single antibody chain or an scFv fragment, a diabody, a single chain comprising complementary scFvs (tandem scFvs) or bispecific tandem scFvs, an Fv construct, a disulfide-linked Fv, a Fab construct, a Fab′ construct, a F(ab′) 2  construct, a monovalent or bivalent construct from which domains non-essential to monoclonal antibody function have been removed, a single-chain molecule containing one VL, one VH antigen-binding domain, and one or two constant “effector” domains optionally connected by linker domains, a univalent antibody lacking a hinge region, a single domain antibody, a dual variable domain immunoglobulin (DVD-Ig) binding protein or a nanobody, an aptamer, an affibody, an affilin, an affitin, an affimer, an alphabody, an anticalin, an avimer, a DARPin, a Fynomer, a Kunitz domain peptide, or a monobody. 
     
     
         6 - 8 . (canceled) 
     
     
         9 . The recombinant, synthetic or monoclonal human antibody or antibody construct according to  claim 2 , which is an IgG. 
     
     
         10 . The recombinant, synthetic or monoclonal human antibody or antibody construct according to  claim 9 , which is an IgG1 isotype. 
     
     
         11 . A recombinant, synthetic or monoclonal human antibody of an IgG class that binds to an epitope, or a fragment of said antibody that binds an epitope, said antibody comprising:
 (a) a nucleotide sequence encoding a heavy chain variable domain sequence that is at least 80% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs. 9, 11 or 13; and   (b) a nucleotide sequence encoding a light chain variable domain sequence that is at least 80% identical to the nucleotide sequence of SEQ ID NOs: 1.   
     
     
         12 . The antibody or epitope binding fragment according to  claim 11 , wherein the antibody comprises a heavy chain and light chain variable domain sequence encoded by SEQ ID NO: 9 and SEQ ID NO: 1 or sequences at least 80% identical thereto. 
     
     
         13 . The antibody or epitope binding fragment according to  claim 11 , wherein the antibody comprises a heavy chain and light chain variable domain sequence encoded by SEQ ID NO: 11 and SEQ ID NO: 1 or sequences at least 80% identical thereto. 
     
     
         14 . The antibody or epitope binding fragment according to  claim 11 , wherein the antibody comprises a heavy chain and light chain variable domain sequence encoded by SEQ ID NO: 13 and SEQ ID NO: 1 or sequences at least 80% identical thereto. 
     
     
         15 . An antigen binding fragment thereof comprising one or more heavy chain CDR selected from the amino acid sequences SEQ ID NOS: 16, 18 or 20 and optionally one of more light chain CDR selected from SEQ ID NO: 4 or 7 or the sequence GIS. 
     
     
         16 - 20 . (canceled) 
     
     
         21 . The antibody or epitope binding fragment according to  claim 1 , wherein said antibody has the FR1/CDR1/FR2/CDR2/FR3CDR3/FR4 sequence combination of the heavy and light chain of mAb 20-10. 
     
     
         22 . An isolated nucleic acid encoding the antibody or epitope according to  claim 1 . 
     
     
         23 . The isolated nucleic acid according to  claim 22 , wherein said nucleic acid is an mRNA. 
     
     
         24 . An mRNA vaccine comprising the mRNA according to  claim 23 . 
     
     
         25 . (canceled) 
     
     
         26 . A pharmaceutical composition for the prevention or treatment of an autoimmune disease comprising at least one antibody or epitope-binding fragment of  claim 1 .